REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Nitrogen Containing Other Than Solely As A Nitrogen In An Inorganic Ion Of An Addition Salt, A Nitro Or A Nitroso Doai > Benzene Ring Containing > Amino Nitrogen Attached To Aryl Ring Or Aryl Ring System By An Acyclic Carbon Or Acyclic Chain > The Aryl Ring Or Aryl Ring System Is Bonded Directly To Another Ring Or Ring System The Aryl Ring Or Aryl Ring System Is Bonded Directly To Another Ring Or Ring SystemThe Aryl Ring Or Aryl Ring System Is Bonded Directly To Another Ring Or Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/07/06 - 20060276550 - Topical compositions of ketamine and butamben and methods of their use Disclosed are pharmaceutical compositions comprising ketamine and butamben. The compositions are useful in the treatment of pain. ... 11/16/06 - 20060258750 - Use of bicyclo[2.2.1]heptane derivatives for the preparation of neuroprotective pharmaceutical compositions The invention relates to the use of compounds of the general Formula (I), wherein R3 stands for hydrogen or hydroxy; R1 stands for hydrogen or alkyl; and R2 stands for alkyl) and pharmaceutically acceptable acid addition salts for the preparation of pharmaceutical compositions having neuroprotective effect. ... 05/18/06 - 20060106114 - Tertiary amino compounds having opioid receptor affinity wherein R1, R2, R3 R4 R5, R6 and N are as disclosed herein. The compounds are useful for the treatment of chronic and acute pain. ... 12/08/05 - 20050272822 - Venlafaxine hydrochloride monohydrate and methods for the preparation thereof This invention relates to novel crystalline polymorphic form of venlafaxine hydrochloride which exists in hydrated form (e.g., as a monohydrate), methods for the preparation thereof, and its use. ... 12/01/05 - 20050267219 - Enantiomers of n-desmethyl venlafaxine The present invention provides enantiomers of N-Desmethyl venlafaxine, as well as their use in pharmaceutical compositions and medically useful treatments, particularly including central nervous system uses. ... 12/01/05 - 20050267218 - 4-hydroxymethyl-1-aryl-cyclohexylamine compounds The invention relates to 4-hydroxymethyl-1-aryl-cyclohexylamine compounds, methods for their production, pharmaceutical formulations containing such compounds and the use of 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives for producing medicines which are useful, for example for treating pain. Related methods of treatment are also provided. ... 11/17/05 - 20050256206 - Enantiomers of o-desmethyl venlafaxine This invention provides pharmaceutically active enantiomers of the venlafaxine metabolite O-Desmethyl venlafaxine, R(−)-4-[2-(Dimethylamino-1-(1-hydroxycyclo-hexyl)ethyl]phenol or R(−)1-[2-(dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclo-hexanol, and S(+)-1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol or S(+)-4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, or one or more pharmaceutically acceptable salts or salt hydrates thereof, as well as pharmaceutical compositions utilizing these enantiomers and methods of using the enantiomers to treat, inhibit or control central ... 11/17/05 - 20050256205 - Crystalline forms of venlafaxine hydrochloride Crystalline forms of Venlafaxine hydrochloride were found, referred to hereinafter as polymorphic Forms A, B and D. Furthermore, the present invention is directed to processes for the preparation of these crystalline forms and pharmaceutical compositions comprising the crystalline forms. ... 10/13/05 - 20050228052 - Methods of treating, preventing and managing a sleep disorder using (s)-didesmethylsibutramine This invention relates, in part, to methods of treating, preventing and/or managing a sleep disorder using enantiomerically pure (S)-didesmethylsibutramine, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate or prodrug thereof. Specific methods for treating, preventing and/or managing insomnia, wakefulness, circadian rhythm sleep disorders, shift work sleep disorder, and periodic limb ... 10/06/05 - 20050222270 - Prolonged administration of nmda antagonist drug and safener drug to create improved stable neural homeostasis An NMDA antagonist (such as ketamine) is administered with a safener (such as clonidine) in patients suffering from neurologic disorders other than pain. The ketamine is adminsitered at a dosage that causes slurred speech, for a span of several days. This treatment enables a patient's nervous system to return to ... 07/07/05 - 20050148673 - Prolonged administration of nmda antagonist and safener drug to alter neuropathic pain condition A drug that inhibits NMDA receptors (such as ketamine, a surgical anesthetic) is continuously administered to patients suffering from neuropathic pain. Unless the NMDA antagonist drug has inherent safening activity, this treatment requires a “safener” drug to prevent the neurotoxic side effects of NMDA antagonists. One class of safener drugs ... 06/16/05 - 20050131074 - Methods for treating metabolic syndrome wherein R1 and R2 are independently H or methyl, and enantiomers and pharmaceutically acceptable salts thereof. ... 06/02/05 - 20050119349 - Process for chlorinating tertiary alcohols The present invention relates to a process for converting a tertiary OH group of an organic compound into a tertiary Cl group of the organic compound by using a solvent selected from the group comprising toluene, o-xylene, m-xylene, p-xylene and mixtures thereof, and thionyl chloride as the chlorinating agent. ... ### FreshPatents.com Support |